Switch theme
Sign up to access all valuation multiples
HLB Life Science Co Ltd is engaged in the energy services and renewable energy businesses. It offers energy-saving facilities, condensing water recovery systems, cogeneration systems, and solar energy development systems. In addition to the existing energy business, the firm is also engaged in investing in new drug development and medical-related field.
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
HLB Life Science has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, HLB Life Science achieved revenue of $69.7M and an EBITDA of $17.6M.
HLB Life Science expects next 12-month revenue of XXX and NTM EBITDA of XXX
See HLB Life Science valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $66.8M | $69.7M | XXX | XXX | XXX |
| Gross Profit | -$2.1M | -$0.5M | XXX | XXX | XXX |
| Gross Margin | -3% | -1% | XXX | XXX | XXX |
| EBITDA | $15.6M | $17.6M | XXX | XXX | XXX |
| EBITDA Margin | 23% | 25% | XXX | XXX | XXX |
| Net Profit | -$37.0M | -$4.1M | XXX | XXX | XXX |
| Net Margin | -55% | -6% | XXX | XXX | XXX |
| Net Debt | $77.3M | $101M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 25, 2025, HLB Life Science's stock price is KRW 6200 (or $4).
HLB Life Science has current market cap of KRW 735B (or $501M), and EV of KRW 780B (or $531M).
See HLB Life Science trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $531M | $501M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 25, 2025, HLB Life Science has market cap of $501M and EV of $531M.
HLB Life Science's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate HLB Life Science's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for HLB Life Science and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $531M | XXX | XXX | XXX |
| EV/Revenue | 7.6x | XXX | XXX | XXX |
| EV/EBITDA | 30.1x | XXX | XXX | XXX |
| P/E | 119.8x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -13.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpHLB Life Science's NTM/LTM revenue growth is n/a
HLB Life Science's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, HLB Life Science's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate HLB Life Science's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for HLB Life Science and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 4% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 13% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 4% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 5% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 18% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| ADNOC Drilling Company | XXX | XXX | XXX | XXX | XXX | XXX |
| ADNOC Gas | XXX | XXX | XXX | XXX | XXX | XXX |
| Dana Gas | XXX | XXX | XXX | XXX | XXX | XXX |
| TAQA | XXX | XXX | XXX | XXX | XXX | XXX |
| AGL Energy | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
HLB Life Science acquired XXX companies to date.
Last acquisition by HLB Life Science was XXXXXXXX, XXXXX XXXXX XXXXXX . HLB Life Science acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was HLB Life Science founded? | HLB Life Science was founded in 1998. |
| Where is HLB Life Science headquartered? | HLB Life Science is headquartered in South Korea. |
| Who is the CEO of HLB Life Science? | HLB Life Science's CEO is Mr. Sang-woo Nam. |
| Is HLB Life Science publicy listed? | Yes, HLB Life Science is a public company listed on KRX. |
| What is the stock symbol of HLB Life Science? | HLB Life Science trades under 067630 ticker. |
| When did HLB Life Science go public? | HLB Life Science went public in 2008. |
| Who are competitors of HLB Life Science? | Similar companies to HLB Life Science include e.g. ADNOC Drilling Company, ADNOC Gas, Dana Gas, TAQA. |
| What is the current market cap of HLB Life Science? | HLB Life Science's current market cap is $501M |
| What is the current revenue growth of HLB Life Science? | HLB Life Science revenue growth between 2023 and 2024 was 4%. |
| Is HLB Life Science profitable? | Yes, HLB Life Science is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
